IMR Press / FBL / Volume 24 / Issue 8 / DOI: 10.2741/4790

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Resveratrol enhances chemosensitivity of renal cell carcinoma to paclitaxel
Show Less
1 Department of Nephrology, Wenling First People’s Hospital of Zhejiang. No. 333, Chuan’an road, Wenling city, Zhejiang province, 317500, People’s Republic of China
Front. Biosci. (Landmark Ed) 2019, 24(8), 1452–1461;
Published: 1 June 2019
(This article belongs to the Special Issue Leader sequences of coronavirus are altered during infection)

By restraining proliferation and promoting apoptosis, resveratrol (RES) has anti-tumor effect in various cancers. Here, we examine whether RES exerts similar effect in drug-resistant renal cell carcinoma (RCC). To this end, Caki-1 cells derived from renal carcinoma are subjected to escalated doses of paclitaxel (PTX) to produce the PTX resistant Caki-1PTX cells. Both Caki-1 and Caki-PTX cells are sensitive to PTX, in a dose dependent manner. RES, dose-dependently, suppresses the expression of survivin, a molecular biomarker of cancer and a member of the inhibitor of apoptosis (IAP) family and its co-administration with PTX inhibits the effect of this drug on cell viability. To decipher whether survivin expressed by cancer cells is involved in rendering cells PTX sensitive, survivin is overexpressed. This dramatically counteracts the effects of RES on cell survival in the presence of PTX. Furthermore, decrease of survivin by inhibition of PI3K/AKT pathway significantly inhibits the effect of PTX in Caki-1PTX cells. These data show that RES increases the sensitivity of PTX resistant renal cells to drug treatment.

Renal cell carcinoma
Figure 1.
Back to top